Fig. 7

The capacity of RM_Score model in predicting immunotherapy response. A The expression of immune-related genes in RM_Score-high and -low subgroups. B Kaplan–Meier curves show overall survival in the RM_Score-high and -low subgroups after the PD-L1 immunotherapy in the IMvigor210 cohort. C The proportion of patients in the IMvigor210 cohort with different responses to PD-L1 blockade immunotherapy. D The difference of clinical outcomes with anti-PD-L1 treatment in the RM_Score high and low subgroups in the IMvigor210 cohort. E The similarity of gene expression profiles between RM patterns and melanoma patients treated with ICB (n = 47). F The RM_Score in three immune subtypes of IMvigor210, including “immune inflamed”, “immune excluded”, and “immune desert”. G, H The TMB and neoantigen burden in the RM_Score-low and RM_Score subgroups. ns, p > 0.05; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001